Pathophysiology of stroke in sickle cell disease

Microcirculation

Volumn 11, Issue 2, 2004, Pages 195-208

  Hillery, Cheryl A ^a,b   Panepinto, Julie A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Hypercoagulable state; Nitric oxide; Oxidative endothelial injury; Red cell adhesion; Sickle cell disease; Stroke

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 8; DEFEROXAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HEPARIN; HYDROXYUREA; PADGEM PROTEIN; TICLOPIDINE; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR; WARFARIN;

BLOOD CLOTTING; BLOOD VESSEL WALL; BRAIN INFARCTION; CEREBRAL ARTERY DISEASE; COGNITION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HUMAN; IRON OVERLOAD; MICROANGIOPATHY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SICKLE CELL ANEMIA; STROKE; SYMPTOM; VASOMOTOR RHINITIS;

ANEMIA, SICKLE CELL; ANIMALS; BLOOD COAGULATION; CELL ADHESION; CEREBRAL ARTERIES; CEREBRAL INFARCTION; CEREBROVASCULAR CIRCULATION; ERYTHROCYTES, ABNORMAL; HUMANS; INFLAMMATION; OXIDATIVE STRESS;

EID: 3242753073     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1080/10739680490278600     Document Type: Review

References (116)

1. Adams RJ, Kutlar A, McKie V, Carl E, Nichols FT, Liu JC, McKie K, Clary A. (1994). Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol 45:279-282.
2. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D, Woods G, Olivieri N, Driscoll C, Miller S, Wang W, Hurlett A, Scher C, Berman B, Carl E, Jones AM, Roach ES, Wright E. (1998). Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339:5-11.
3. Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. (1988). Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology 38:1012-1017.
4. Alkjaersig N, Fletcher A, Joist H, Chaplin H Jr. (1976). Hemostatic alterations accompanying sickle cel] pain crises. J Lab Clin Med 88:440-449.
5. Arena JM. (1939). Cerebral vascular lesions accompanying sickle-cell anemia. J Pediatr 14:745-751.
6. Armstrong FD, Thompson RJ, Jr., Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K. (1996). Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Commitee of the Cooperative Study of Sickle Cell Disease. Pediatrics 97:864-870.
7. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. (2001). Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98:15215-15220.
8. Balasa VV, Gruppo RA, Gartside PS, Kalinyak KA. (1999). Correlation of the C677T MTHFR genotype with homocysteine levels in children with sickle cell disease. J Pediatr Hematol Oncol 21:397-400.
9. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. (1992). Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 120:360-366.
10. Beurling-Harbury C Schade SG. (1989). Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol 31:237-241.
11. Bridgers WH. (1939). Cerebral vascular disease accompanying sickle cell anemia. Am J Pathol 15:353-361.
12. Browne PV, Mosher DF, Steinberg MH, Hebbel RP. (1996). Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 51:296-301.
13. Buchanan GR, Holtkamp CA. (1983). Evidence against enhanced platelet activity in sickle cell anaemia. Br J Haematol 54:595-603.
14. Carvalho KS, Garg BP. (2002). Arterial strokes in children. Neurol Clin 20:1079-1100.
15. Chaplin HJ, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. (1980). Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost 43:218-221.
16. Chaplin HJ, Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA. (1989). Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J 66:574-584.
17. Craft S, Schatz J, Glauser TA, Lee B, DeBaun MR. (1993). Neuropsychologic effects of stroke in children with sickle cell anemia J Pediatr 123:712-717.
18. Cumming AM, Olujohungbe A, Keeney S, Singh H, Hay CR, Serjeant GR. (1999). The methylenete-trahydrofolate reductase gene C677T polymorphisim in patients with homozygous sickle cell disease and stroke. Br J Haematol 107:569-571.
19. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. (2000). Inflammation and stroke: putative role for cytokines. adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 10:95-112.
20. DeVeber G. (2002). Stroke and the child's brain: an overview of epidemiology, syndromes and risk factors. Curr Opin Neurol 15:133-138.
21. Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D, Abboud MR. (2002). Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent, cerebrovascular events. Blood 99:3144-3150.
22. Driscoll MC, Hurlet A, Styles L, MoVie V, Files B, Olivieri N, Pegelow C, Berman B, Drachtman R, Patel K, Brambilla D. (2003). Stroke risk in siblings with sickle cell anemia. Blood 101:2401-2404.
23. Du LM, Holzman SL, Mohandas N, Scott JP, Trost BA, Hillery CA. (2000). Increased fibrin deposition at sites of vasoocclusion in transgenic sickle mice. Blood 96:16 (Abstr).
24. Fabry ME, Sengupta A, Suzuka SM, Costantini F, Rubin EM, Hofrichter J, Christoph GW, Manci E, Culberson D, Factor SM, et a]. (1995). A second generation transgenic mouse model expressing both hemoglobin S (HbS). and HbS-Antilles results in increased phenotypic severity. Blood 86:2419-2428.
25. Fabry ME, Suzuka SM, Weinberg RS, Lawrence C, Factor SM, Gilman JG, Costantini F, Nagel RL. (2001). Second generation knockout sickle mice: the effect of HbF. Blood 97:410-418.
26. Faraci FM, Brian JE Jr. (1994). Nitric oxide and the cerebral circulation. Stroke 25:692-703.
27. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse MF, Feremans W, Hunninck K, Toppet M, Philippet P, Van Geet C, Sariban E. (2001). Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97:3628-3632.
28. Francis RB Jr. (1988). Protein S deficiency in sickle cell anemia. J Lab Clin Med 111:571-576.
29. Francis RB Jr. (1989). Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 19:105-111.
30. Francis RB Jr. (1991). Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 2:341-353.
31. Francis RB Jr. (1991). Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 2:341-353.
32. Franck PFH, Bevers EM, Lubin BH, Comfurius P, Chiu DT, Op den Kamp JA, Zwaal RFA, van Deenen LL, Roelofsen B. (1985). Uncoupling of the membrane skeleton from the lipid bilayer: the cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickle cells. J Clin Invest 75:183-190.
33. French JA, II, Kenny D, Scott JP, Hoffmann RG, Wood JD, Hudetz AG, Hillery CA. (1997). Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood 89:4591-4599.
34. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, Navab M, Fogelman AM, Segrest JP, Anantharamaiah GM. (2001). A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 42:545-552
35. Gee BE, Platt OS. (1995). Sickle reticulocytes adhere to VCAM-1 Blood 85:268-274.
36. Gerald B, Sebes JI, Langston JW. (1980). Cerebral infarction secondary to sickle cell disease: arteriographic findings. AJR Am J Roentgenol 134:1209-1212.
37. Glauser TA, Siegel MJ, Lee BC, DeBaun MR. (1995). Accuracy of neurologic examination and history in detecting evidence of MRI-diagnosed cerebral infarctions in children with sickle cell hemoglobinopathy. J Child Neurol 10:88-92.
38. Grabowski EF. (2002). Congenital and aquired prothrombotic risk factors in stroke. Curr Opin Neurol 15:139-144.
39. Granfortuna J, Zamkoff K, Urrutia E. (1986). Acute renal infarction in sickle cell disease. Am J Hematol 23:59-64.
40. Green D, Scott JP. (1986). Is sickle cell crisis a thrombotic event? Am J Hematol 23:317-321.
41. Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. (1983). Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 102:781-784.
42. Hillery CA, Du MC, Montgomery RR, Scott JP. (1996). Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood 87:4879-4886.
43. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L. (2003). Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 101:2865-2869.
44. Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro OL. (1997). Homocysteine in sickle cell disease: relationship to stroke. Am J Med 103:192-196.
45. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. (1996). Enlarged infarets in endothelial nitric oxide synthase knockout mice are attenuated by intro-L-arginine. J Cereb Blood flow Metab 16:981-987.
46. Iadecola C, Pelligrino DA, Moskowitz MA, Lassen NA. (1994). Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 14:175-192.
47. Iannone R, Casella JF, Fuch EJ, et al. (2003). Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 9:519-528.
48. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. (1997). Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease. Clin Neurol Neurosurg 99(Suppl 2 ):S234-S237.
49. Kahn MJ, Scher C, Rozans M, Michaels RK, Leissinger C, Krause J. (1997). Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Am J Hematol 54:12-15.
50. Kaul DK, Hebbel RP. (2000). Hypoxia/ reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 106:411-420.
51. Kaul DK, Liu XD, Fabry ME, Nagel RL. (2000). Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol 278:H1799-H1806.
52. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, Wethers DL, Bello JA, Vichinsky EP, Moser FG, Gallagher DM, DeBaun MR, Platt OS, Miller ST. (1999). Silent cerebral infarets in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 103:640-645.
53. Koshy M, Thomas C, Goodwin J. (1990). Vascular lesions in the central nervous system in sickle cell disease. J Assoc Acad Minor Phys 1:71-78.
54. Kurantsin-Mills J, Ibe BO, Natta CL, Raj JU, Siegel RS, Lessin LS. (1994). Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation. Br J Haematol 87:580-585.
55. Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS. (1992). Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 81:539-544.
56. Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernest JD, Lubin BH. (1996). Detection of altered membrane phospholopid assymmetry in subpopulations of human red blood cells using flourescently labeled Annexin V. Blood 87:1179-1187.
57. Lynch GF, Gorelick PB. (2000). Stroke in African Americans. Neurol Clin 18:273-290.
58. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. (2000). The novel adhesion of erythrocytes to P-selectin in sickle cell disease. Blood 96:600a (Abstr).
59. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt LD, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vichinsky EP, Wang WC, Wethers DL, Younkin DP, Zimmerman RA, DeBaun MR. (2001). Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 139: 385-390.
60. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. (2000). Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 342:83-89.
61. Moser FG, Miller ST, Bello JA, Pegelow CH, Zimmerman RA, Wang WC, Ohene-Frempong K, Schwartz A, Vichinsky EP, Gallagher D, Kinney TR. (1996). The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 17:965-972.
62. Nagel RL, Fabry ME. (2001). The panoply of animal models for sickle cell anaemia. Br J Haematol 112:19-25.
63. Natarajan M, Udden MM, McIntire LV. (1996). Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Blood 87:4845-4852.
64. Nath KA, Shah V, Haggard JJ, Croatt AJ, Smith LA, Hebbel RP, Katusic ZS. (2000). Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 279:R1949-R1955.
65. Navab M, Hama SY, Ready ST, Ng CJ, Van Lenten BJ, Laks H, Fogelman AM. (2002). Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 13:363-372.
66. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. (1998). Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91:288-294.
67. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. (2000). Reperfusion injury pathophysiology in sickle transgenic mice. Blood 96:314-320.
68. Ou J, Ou Z, Jones DW, Holtzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA. (2003). L-4F, an apo A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107:2337-2341.
69. Pàszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, Rubin EM. (1997). Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278:876-878.
70. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D. (1995). Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 126:896-899.
71. Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR. (2002). Longitudinal changes in brain Magnetic resonance imaging findings in children with sickle cell disease. Blood 99:3014-3018.
72. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. (1994). Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 71:169-172.
73. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. (1994). Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
74. Powars D, Wilson B, Imbus C, Pagalow C, Allen J. (1978). The natural history of stroke in sickle cell anemia. Am J Med 65:461-471.
75. Powars DR. (1991). Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol 28:202-208.
76. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ. (2002). Sickle cell disease: the neurological complications. Ann Neurol 51:543-552.
77. Punzalan RC, Holzman SL, Trost BA, Pàzty C, Mohandas N, Scott JP, Hillery CA. (1999). Spontaneous stroke and increased erythrocyte adhesion in transgenic knockout sickle cell mice. Blood 94:419a (Abstr).
78. Punzalan RC, Trost BA, Scott JP, Huderz AG, Hillery CA. (1998). Chondroitin sulfate-A limits cerebral ischemia induced by nitric oxide inhibition in sickle erthrocyte-infused rats. Blood 92:329a (Abstr).
79. Rothman SM, Fulling KH, Nelson JS. (1986). Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol 20:684-690.
80. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. (1984). Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 63:162-169.
81. Ryan TM, Ciavatta DJ, Townes TM. (1997). Knockout-transgenic mouse model of sickle cell disease. Science 278:873-876.
82. Salvaggio JE, Arnold CA, Banov CH. (1963). Long-term anticoagulation in sickle cell disease. N Engl J Med 269:182-186.
83. Sarnaik SA, Ballas SK. (2001). Molecular characteristics of pediatric patients with sickle cell anemia and stroke. Am J Hematol 67:179-182.
84. Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. (2001). Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 56:1109-1111.
85. Schnog JB, Kater AP, Mac Gillavry MR, Duits AJ, Lard LR, Der Dijs FP, Brandjes DP, ten Cate H, van Eps LW, Rojer RA. (2001). Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol 68:179-183.
86. Schnog JB, Mac Gillavry MR, Rojer RA, Meijers JC, Fijnheer R, ten Cate H, Brandjes DP, Duits AJ. (2002). No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. Am J Hematol 71:53-55.
87. Scothorn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, Sarniak I, Fallon R, Chu JY, Pegelow CH, Wang W, Casella JF, Resar LS, Berman B, Adamkiewicz T, Hsu LL, Ohene-Frempong K, Smith-Whitley K, Mahoney D, Scott JP, Woods GM, Watanabe M, DeBaun MR. (2002). Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 140:348-354.
88. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. (1984). A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 51:303-306.
89. Setty BN, Chen D, Stuart MJ. (1995). Sickle cell vasoocclusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids. Pediatr Res 38:95-102.
90. Setty BN, Kulkarni S, Rao AK, Stuart MJ. (2000). Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood 96:1119-1124.
91. Solovey A, Gui L, Key NS, Hebbel RP. (1998), Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 101: 1899-1904.
92. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. (1997). Circulating activated enclothelial cells in sickle cell anemia. N Engl J Med 337:1584-1590.
93. Steen RG, Helton KJ, Horwitz EM, Benaim E, Thompson S, Bowman LC, Krance R, Wang WC, Cunningham JM. (2001). Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol 49:222-229.
94. Stockman JA, Nigro MA, Mishkin MM, Oski FA. (1972). Occlusion of large cerebral vessels in sickle cell anemia. N Engl J Med 287:847-849.
95. Stuart J, Stone PC, Akinola NO, Gallimore JR, Pepys MB. (1994). Monitoring the acute phase response to vasoocclusive crisis in sickle cell disease. J Clin Pathol 47:166-169.
96. Stuart MJ, Setty BN. (1999). Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 94:1555-1560.
97. Stuart MJ, Stockman JA, Oski FA. (1974). Abnormalities of platelet aggregation in the vasoocclusive crisis of sickle-cell anemia. J Pediatr 85:629-632.
98. Sumoza A, de Bisotti R, Sumoza D, Fairbanks V. (2002). Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 71:161-165.
99. 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-l-dependent binding to endothelium. Blood 82:1891-1899.
100. Sydenstricker VP, Mulherin WA, Houseal RW. (1923). Sickle cell anemia: report of two cases in children, with necropsy in one case. Am J Dis Child 26:132-154.
101. Tagami M, Ikeda K, Nara Y, Fujino H, Kubota A, Numano F, Yamori Y. (1995). Detailed examination of vascular lesions triggered by an inhibitor of endothelium-derived relaxing factor. Lab Invest 72:174-182.
102. Tam DA. (1997). Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 12:19-21.
103. Tang DC, Prauner R, Liu WL, Kim KH, Hirsch RP, Driscoll MC, Rodgers GP. (2001). Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol 68:164-169.
104. Taylor JG, Tang DC, Savage SA, Leitman SF, Heller SI, Serjeant GR, Rodgers GP, Chanock SJ. (2002). Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 100:4303-4309.
105. Tuohy AM, McKie V, Manci EA, Adams RJ. (1997). Internal carotid artery occlusion in a child with sickle cell disease: case report and immunohistochemical study. J Pediatr Hematol Oncol 19:455-458.
106. Vichinsky EP, Lubin BH. (1994). A cautionary note regarding hydroxyurea in sickle cell disease. Blood 83:1124-1128.
107. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GE, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Dickerhoff R, Yeager AM, Hsu L, Kurtzberg J, Ohene-Frempong K, Bunin N, Bernaudin F, Wong WY, Scott JP, Margolis D, Vichinsky E, Wall DA, Wayne AS, Pegelow C, Redding-Lallinger R, Wiley J, Klemperer M, Mentzer WC, Smith FO, Sullivan KM. (2000). Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 95:1918-1924.
108. Wang W, Enos L, Gallagher D, Thompson R, Guarini L, Vichinsky E, Wright E, Zimmerman R, Armstrong FD. (2001). Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 139:391-397.
109. Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, Schell MJ, Wilimas JA. (1991). High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 118:377-382.
110. Ware RE, Zimmerman SA, Schultz WH. (1999). Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94:3022-3026.
111. Westwick J, Watson-Williams EJ, Krishnamurthi S, Marks G, Ellis V, Scully MF, White JM, Kakkar VV. (1983). Platelet activation during steady state sickle cell disease. J Med 14:17-36.
112. Wolters HJ, ten Cate H, Thomas LL, Brandjes DP, van der Ende A, van der Heiden Y, Statius vEL. (1995). Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment? Br J Haematol 90:715-717.
113. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. (1997). Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 129:507-516.
114. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue T, Ikezaki K, Matsushima T, Fukui M. (2000). Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31:930-935.
115. Zago MA, Costa FF, Ismael SJ, Tone LG, Bottura C. (1984). Treatment of sickle cell diseases with aspirin. Acta Haematol 72:61-64.
116. Zimmerman SA, Ware RE. (1998). Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol 59:267-272.